Mitochondrial Peptides: What the Record Actually Shows
SS-31 and MOTS-c are the two mitochondrial peptides most often sequenced against each other, usually with SS-31 first. One of them has been through a pivotal phase 3 trial. The other has never been given to a human in a controlled study of any outcome that matters.
Both facts are checkable, and the gap between them is the most useful thing in this article.
SS-31 / elamipretide: a full clinical record, including the miss
Elamipretide binds cardiolipin at the inner mitochondrial membrane, which is the mechanistic claim behind nearly all of the interest in it. That mechanism has now been tested in the one setting where mitochondrial dysfunction is the disease rather than an inference.
MMPOWER-3 was a phase 3, randomised, double-blind, placebo-controlled trial in primary mitochondrial myopathy: 218 participants, 24 weeks, subcutaneous dosing, with two primary endpoints — distance walked in six minutes and total fatigue on a disease-specific symptom scale (PMID 37268435).
Both primary endpoints were missed, and not narrowly: the difference in six-minute walk distance was −3.2 metres (95% CI −18.7 to 12.3; p = 0.69), and the fatigue difference was −0.07 (95% CI −0.10 to 0.26; p = 0.37). The drug was well tolerated, with mostly mild-to-moderate adverse events. Earlier, smaller trials in the same population had looked more encouraging — a dose-escalation study (PMID 29500292) and a randomised crossover trial (PMID 32096613) — which is a familiar shape in this field: small positive signals, then a large trial that does not confirm them. A post-hoc analysis went looking for genotype-specific effects, which is what you do when the headline result is negative (PMID 39574155).
Then the same compound was approved for something else. Elamipretide (Forzinity) received accelerated approval in the United States to improve muscle strength in patients with Barth syndrome weighing 30 kg or more, making it the first disease-specific treatment approved for that ultra-rare X-linked condition (PMID 41335372). Barth syndrome data include a 168-week open-label extension (PMID 38602181), and the mechanism keeps being pursued elsewhere — dry age-related macular degeneration is still in phase III development, with phase II results already published (PMID 39605874).
Two things are true at once, and both matter: elamipretide failed a pivotal trial in one mitochondrial disease and became the first approved treatment in another. Anyone citing “the SS-31 trials” without naming which disease and which trial is not describing the record.
MOTS-c: the other tier entirely
MOTS-c is a mitochondrial-derived peptide, and its human record is not small — it is a different kind of record.
The founding study, in 2015, was in mice: MOTS-c promoted metabolic homeostasis and reduced obesity and insulin resistance (PMID 25738459). That paper is cited constantly, and it is a mouse paper.
Since then the work has largely been mechanistic, and some of it is genuinely interesting — MOTS-c improving intrinsic muscle mitochondrial bioenergetics through a PGC-1α/AMPK-linked pathway (PMID 41520850), and directly binding and activating CK2 in skeletal muscle (PMID 39559755). The reviews that describe it as promising for therapeutic use are describing preclinical promise (PMID 36233287).
What exists on the human side is measurement, not intervention: circulating MOTS-c levels studied in relation to disease and treatment — for example, levels in patients with breast cancer treated with metformin (PMID 36490309). Levels correlating with something is a hypothesis generator. It is not an outcome, and no controlled trial has given MOTS-c to people and measured whether anything improved.
So when SS-31 and MOTS-c are described together as “the mitochondrial peptides”, they are being described together by category, not by evidence. One has a phase 3 trial, an approval, and a miss. The other has mouse and cell data, plus human correlations. Those tiers should not be spoken in the same voice.
Why the priming sequence is where the argument actually lives
The sequence people use — SS-31 first, then MOTS-c later — is an arrangement, and arrangements have their own evidence problem. Nothing in the literature tests that order. There is no trial of SS-31 followed by MOTS-c against either alone, and there is no established endpoint that would tell you the first item did anything to enable the second.
That does not make the arrangement unreasonable to track. It makes the attribution question the interesting one, and it can only be answered by what is measured: one endpoint per item, and a period where the first item is removed to see whether the second behaves differently. Without that, a priming sequence and a coincidence with identical timing are indistinguishable.
The reference side carries what is published — the SS-31 preparation and schedule — and the planner will lay the sequence out week by week, including the offset start, as a display of the arrangement rather than a recommendation of it.
What’s next in the Rebuild Log
The next entry stays with the primer: what the first item in a sequence is supposed to be doing mechanistically, what a reader should accept as evidence it did that, and what happens to the second item’s result when the first is taken away.
What this is: one problem examined in research context. N=1 accounts appear in this series only when a contributor’s own log supports them. Not medical advice · no causality claimed · 18+. Elamipretide’s pivotal trial in primary mitochondrial myopathy missed both primary endpoints; MOTS-c has no controlled human outcome data. Trial references are listed so you can read them directly.